NAV

Verpasep caltespen

Identification

Generic Name
Verpasep caltespen
DrugBank Accession Number
DB04959
Background

HspE7 is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. It is being developed by StressGen Biotechnologies Corp.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Recombinant
Synonyms
  • BCG65-E7
  • Heat-shock protein HSP 65 (Mycobacterium BCG) fusion protein with transcription factor E7 (human papillomavirus 16)
  • HPV 16 E7/HSP65 vaccine
  • HPV E7 Peptide Epitope Vaccine
  • HspE7
  • Verpasep caltespen
External IDs
  • SGN-00101

Pharmacology

Indication

Investigated for use/treatment in anal dysplasia, cervical dysplasia/cancer, genital warts, HIV infection, infectious and parasitic disease (unspecified), pediatric indications, warts, and viral infection.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

HspE7 works by efficiently delivering the E7 antigen to dendritic cells, which have a natural affinity for Hsp. Dendritic cells are known to be the most potent cells in the body for triggering immune responses. Coupling E7 to Hsp takes advantage of the Hsp receptors that dendritic cells express on their surface to introduce E7, as part of a larger fusion protein, into the dendritic cells.

TargetActionsOrganism
UKeratin, type II cytoskeletal 7Not AvailableHumans
UE3 ubiquitin-protein ligase UBR4Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Z7T0JI2E2I
CAS number
295371-00-5

References

General References
  1. Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY: A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS. 2006 May 12;20(8):1151-5. [Article]
  2. Hunt S: Technology evaluation: HspE7, StressGen Biotechnologies Corp. Curr Opin Mol Ther. 2001 Aug;3(4):413-7. [Article]
  3. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR: Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum. 2002 Apr;45(4):502-7. [Article]
  4. Maciag PC, Paterson Y: Technology evaluation: HspE7 (Stressgen). Curr Opin Mol Ther. 2005 Jun;7(3):256-63. [Article]
  5. Derkay CS, Smith RJ, McClay J, van Burik JA, Wiatrak BJ, Arnold J, Berger B, Neefe JR: HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol. 2005 Sep;114(9):730-7. [Article]
PubChem Substance
347909860
Wikipedia
HspE7

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionAtypical Squamous Cells of Undetermined Significance / Cervical Cancer / HSIL, High Grade Squamous Intraepithelial Lesions / LSIL, Low-Grade Squamous Intraepithelial Lesions1
2CompletedPreventionCervical Cancer / Precancerous Conditions1
2CompletedTreatmentCervical Cancer / Cervical Intraepithelial Neoplasia, Grade III / Human Papillomavirus (HPV) Infections1
2CompletedTreatmentPapilloma / Recurrent Respiratory Papillomatosis1
2Unknown StatusTreatmentPrecancerous Conditions1
1Unknown StatusNot AvailableCervical Intraepithelial Neoplasia (CIN)1
1, 2CompletedPreventionAnal Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Keratin, type II cytoskeletal 7
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Structural molecule activity
Specific Function
Blocks interferon-dependent interphase and stimulates DNA synthesis in cells. Involved in the translational regulation of the human papillomavirus type 16 E7 mRNA (HPV16 E7).
Gene Name
KRT7
Uniprot ID
P08729
Uniprot Name
Keratin, type II cytoskeletal 7
Molecular Weight
51385.11 Da
References
  1. Kanduc D: Translational regulation of human papillomavirus type 16 E7 mRNA by the peptide SEQIKA, shared by rabbit alpha(1)-globin and human cytokeratin 7. J Virol. 2002 Jul;76(14):7040-8. [Article]
Details2. E3 ubiquitin-protein ligase UBR4
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule,...
Gene Name
UBR4
Uniprot ID
Q5T4S7
Uniprot Name
E3 ubiquitin-protein ligase UBR4
Molecular Weight
573835.26 Da
References
  1. Huh KW, DeMasi J, Ogawa H, Nakatani Y, Howley PM, Munger K: Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11492-7. Epub 2005 Aug 1. [Article]

Drug created at October 21, 2007 22:23 / Updated at February 21, 2021 18:51